- Home
- WEA vs EDIT Comparison
WEA vs EDIT Comparison
Compare WEA & EDIT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- WEA
- EDIT
- Stock Information
- Founded
- WEA 2002
- EDIT 2013
- Country
- WEA United States
- EDIT United States
- Employees
- WEA N/A
- EDIT N/A
- Industry
- WEA Trusts Except Educational Religious and Charitable
- EDIT Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- WEA Finance
- EDIT Health Care
- Exchange
- WEA Nasdaq
- EDIT Nasdaq
- Market Cap
- WEA 131.1M
- EDIT 108.1M
- IPO Year
- WEA N/A
- EDIT 2016
- Fundamental
- Price
- WEA $10.89
- EDIT $1.92
- Analyst Decision
- WEA
- EDIT Buy
- Analyst Count
- WEA 0
- EDIT 14
- Target Price
- WEA N/A
- EDIT $8.08
- AVG Volume (30 Days)
- WEA 46.1K
- EDIT 5.8M
- Earning Date
- WEA 01-01-0001
- EDIT 03-03-2025
- Dividend Yield
- WEA 7.87%
- EDIT N/A
- EPS Growth
- WEA N/A
- EDIT N/A
- EPS
- WEA N/A
- EDIT N/A
- Revenue
- WEA N/A
- EDIT $61,759,000.00
- Revenue This Year
- WEA N/A
- EDIT N/A
- Revenue Next Year
- WEA N/A
- EDIT N/A
- P/E Ratio
- WEA N/A
- EDIT N/A
- Revenue Growth
- WEA N/A
- EDIT 150.95
- 52 Week Low
- WEA $9.60
- EDIT $1.12
- 52 Week High
- WEA $11.29
- EDIT $11.58
- Technical
- Relative Strength Index (RSI)
- WEA 46.16
- EDIT 55.72
- Support Level
- WEA $10.90
- EDIT $1.12
- Resistance Level
- WEA $11.05
- EDIT $3.30
- Average True Range (ATR)
- WEA 0.13
- EDIT 0.30
- MACD
- WEA -0.01
- EDIT 0.12
- Stochastic Oscillator
- WEA 28.00
- EDIT 36.70
About WEA Western Asset Bond Fund Share of Beneficial Interest
Western Asset Premier Bond Fund is a diversified, closed-end management investment company. Its investment objective is to provide current income and capital appreciation by investing in a diversified portfolio of investment-grade bonds. The Fund invests in sectors, such as financials, energy, telecommunication services, consumer discretionary, healthcare, materials, information technology, and consumer staples.
About EDIT Editas Medicine Inc.
Editas Medicine Inc is a clinical-stage genome editing company dedicated to developing potentially transformative genomic medicines to treat a broad range of serious diseases. The company focuses on developing a proprietary genome editing platform based on clustered, regularly interspaced short palindromic repeats (CRISPR)/ CRISPR-associated protein 9 (Cas9 technology). It has developed CRISPR/Cas9 technology which uses a protein-RNA (ribonucleic acid) complex composed of the Cas9 enzyme bound to a guide RNA molecule designed to recognize a DNA (deoxyribonucleic acid) sequence that requires repair. The company is engaged in developing and commercializing genome editing technology.